High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.